Therapeutic compounds having increased resistance to deamination and
inactivation by metabolic enzymes are provided. The compounds include
nucleotide analogs and nucleotide analogs, derivatized with aminal and/or
thioaminal groups to prevent deamination of free amine. The compounds can
be used in a variety of treatments, including treatment of neoplastic
disorders, infections from fungal or fungal-like organisms, and
infections from parasites.